1 row is stored for this page
| Field | Field type | Value |
|---|
| generic | String | Morphine (sulfate) |
| brand | String | MS Contin (ER), Kadian (ER), Avinza (ER), Roxanol (IR oral solution), Duramorph (epidural / IT), Astramorph (IV), Infumorph (intrathecal pump), MorphaBond (IR abuse-deterrent) |
| structure | File | |
| classes | List of String, delimiter: , | [[:Category:Opioid analgesics|Opioid analgesic (natural phenanthrene from opium poppy)]] • [[:Category:Schedule II controlled substances|Schedule II controlled substance]] • [[:Category:Analgesics|Analgesic]] |
| mechanism | String | |
| uses | String | '"`UNIQ--vote-0000001B-QINU`"', '"`UNIQ--vote-0000001C-QINU`"', '"`UNIQ--vote-0000001D-QINU`"', '"`UNIQ--vote-0000001E-QINU`"', '"`UNIQ--vote-0000001F-QINU`"' |
| starting_dose | String | IR oral: 15-30 mg every 4 hours as needed. ER opioid-naive: 15-30 mg every 12 hours. IV/IM/SC: 2-10 mg every 3-4 hours. Epidural / intrathecal: see surgical or palliative-care protocols |
| preparations | String | IR tablets 15, 30 mg; oral solution 10 mg/5 mL, 20 mg/mL, 100 mg/5 mL (concentrated); suppositories; ER tablets and capsules in multiple strengths; injectable 0.5-50 mg/mL |
| fda_max | String | No fixed ceiling; titrate to clinical effect and tolerability with CDC opioid prescribing guidance constraints on morphine-milligram-equivalent (MME) totals |
| pill_id | Text | |
| routes | List of String, delimiter: , | Oral • intravenous • intramuscular • subcutaneous • epidural • intrathecal • rectal |
| onset | String | 5-10 minutes (IV); 30 minutes (oral IR); slower for ER and rectal |
| duration | String | 3-5 hours (IR); 8-24 hours (ER); 12-24 hours (epidural / intrathecal) |
| halflife | String | Morphine 2-4 hours; morphine-6-glucuronide active metabolite 2-4 hours (longer with renal impairment)'"`UNIQ--ref-00000020-QINU`"' |
| bioavailability | String | ~25-40% (oral; extensive first-pass)'"`UNIQ--ref-00000021-QINU`"' |
| pregnancy | String | Chronic third-trimester exposure produces neonatal opioid withdrawal syndrome and respiratory depression at delivery.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> |
| legal | String | [[USLegal:Schedule II|Schedule II controlled substance]] in US; WHO essential medicine'"`UNIQ--ref-00000022-QINU`"' |
